Market News How it works Learn FAQ
| TGL 0.2897 30.79% | SRTM 0.6164 43.25% | NU 11.845 -21.87% | GCDT 0.1604 -8.92% | EWZ 31.98 -24.91% | NWGL 0.0808 -1.46% | SHFS 0.1254 -5.29% | RBNE 0.183 -3.68% | CLRO 4.2705 31.40% | SPRC 1.635 50.00% | SOXL 87.29 4.46% | BBD 2.9088 -28.53% | VBIO 0.785 -16.49% | RENT 2.85 23.91% | ITUB 7.63 -21.10% | PBR 21.675 -17.14% | SOXS 50.2 -4.31% | TSLL 10.68 9.43% | SPCX 147.12 -0.25% | XP 14.42 -52.58% | XXII 0.1032 -47.80% | GPUS 0.1583 -6.28% | WFF 0.0741 -7.38% | KORU 10.59 0.09% | CRWV 52.0841 -3.97% | IREN 24.13 -3.11% | STNE 7.83 -31.79% | SQQQ 39.02 -1.66% | PRSO 0.35 -7.51% | NOK 8.44 3.69% | INTR 4.751 -33.92% | MYND 0.2219 -7.54% | TQQQ 67.37 1.63% | INTC 88.11 1.32% | VALE 12.27 -1.05% | NVDA 214.88 1.86% | TSLA 389.99 4.77% | VZ 43.45 -2.71% | IBIT 44.9769 -2.14% | WORX 2.2101 0.92% | YMAT 2.25 9.76% | AZTR 0.9102 1,173.01% | JBLU 2.4312 -7.38% | STLA 4.105 1.11% | WULF 11.36 0.35% | T 21.075 0.69% | IRE 2.9 -6.15% | PAGS 8.6 -24.83% | META 631.35 -1.75% | NBIS 151.07 -4.83%
MLMineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS)

NASDAQ Global Select · Currency in USD
$20.52 ▼ -0.03 (-0.15%)
As of Oct 26, 9:49 AM ET. Market open.

Summary

Previous Close
$20.55
Open
$20.71
Day's Range
$20.31 – $20.84
52 Week Range
$20.12 – $47.65
Volume
45,597
Avg. Volume
1,194,186
Market Cap
$1.81B
Beta (5Y Monthly)
0.69
PE Ratio (TTM)
--
EPS (TTM)
-$4.13
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$29.00

Profile: Mineralys Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
76
CEO
Jon Congleton

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.55
DateEst.Actual
Aug 12, 2026-$0.55-$2.85Miss
May 6, 2026-$0.51-$0.47Beat
Mar 12, 2026-$0.52-$0.40Beat
Nov 10, 2025-$0.66-$0.52Beat
Aug 12, 2025-$0.78-$0.66Beat
May 12, 2025-$1.02-$0.79Beat

Analyst view

Consensus price target
$29.00 ▲ +41.3%
Range $29.00 – $29.00
Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on MLYS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.